FAHA

Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update

Retrieved on: 
Martedì, Agosto 2, 2022
Sale, PIN, University, GLOBE, Awareness, Mortality, Treasury, Research, Twitter, U.S. Securities and Exchange Commission, Moyamoya disease, Hypercholesterolemia, University of Texas Southwestern Medical Center, Bempedoic acid, Tablet, FACC, Development, General officer, Cardiovascular disease, Forward-looking statement, Partnership, CVD, Health, Risk, Disease, COVID-19, Targeted molecular therapy for neuroblastoma, Administration, NASDAQ, Coronavirus Scientific Advisory Board (Turkey), Adoption, ESPR, FAHA, FDA, Company, Security (finance), Patient, Cholesterol, Therapy, Harvard Medical School, Growth, ANN, Mallinckrodt, Ezetimibe, MACE, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Lithium, Esperies, MD

ANN ARBOR, Mich., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

Key Points: 
  • Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023
    ANN ARBOR, Mich., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
  • These results remain of critical importance for millions of patients globally with or at risk for cardiovascular disease.
  • Esperion had net losses of $66.3 million for the second quarter of 2022 and $123.1 million for the six months ended June 30, 2022, compared to net losses of $43.7 million and $134.6 million for the comparable periods in 2021.
  • Esperion expects full-year 2022 operating expenses to be approximately $220 million to $240 million, inclusive of $25 million of non-cash, stock-based compensation expense.

MarinHealth Receives National Recognition for Commitment to Providing High-Quality Stroke Care

Retrieved on: 
Giovedì, Luglio 14, 2022
Hospitals, Health, Fitness & Nutrition, Cardiology, Managed Care, Knowledge, American Heart Association, Achievement, Compliance, FAHA, No, Patient, CEO, Mortality, Stroke, Heart failure, Degenerative disease, Guideline, Death, Gold, American Heart, Infarction, Health, Hospital, University of Texas Southwestern Medical Center, Calendar, Thrombolysis, Association, Pharmaceutical industry, Medicine

Every 40 seconds, someone in the U.S. has a stroke or heart attack, and heart disease and stroke are the No.

Key Points: 
  • Every 40 seconds, someone in the U.S. has a stroke or heart attack, and heart disease and stroke are the No.
  • As a participant in Get With The Guidelines program, MarinHealth qualified for the awards by demonstrating its deep commitment to continually improving quality of care.
  • MarinHealth is committed to improving care for patients by adhering to the latest treatment guidelines and streamlining processes to ensure timely and proper care for heart attacks and stroke, said Dr. David Klein, CEO of MarinHealth.
  • MarinHealth Medical Center, the MarinHealth Medical Network, and their ancillary services all share the same patient-centric philosophy of care.

Highland Hospital is nationally recognized for its commitment to providing high-quality cardiovascular care

Retrieved on: 
Venerdì, Giugno 17, 2022
Alameda Health System, Association, STEMI, Mortality, Infarction, Stroke, Achievement, American Heart Association, University of Texas Southwestern Medical Center, Highland Hospital, AHS, Hospital, Physician, Emergency medical services, Program, Guideline, Education, American Heart, FAHA, Death, Patient, Health, Cardiology, Degenerative disease, Pharmaceutical industry, Medicine

ALAMEDA, Calif., June 17, 2022 /PRNewswire/ -- Alameda Health System's Highland Hospital has received two American Heart Association achievement awards for delivering the latest, research-based treatments of heart disease and stroke, ultimately leading to more lives saved, shorter recovery times and fewer readmissions to the hospital.

Key Points: 
  • The American Heart Association presented Highland Hospital with Get With The Guidelines and Mission: Lifelineawards for proven dedicationto best practices and life-saving care.
  • As a participant in both programs, Highland Hospital qualified for the Get With The Guidelines and Mission: Lifeline awards by demonstrating how their organization has committed to improving quality care.
  • ALAMEDA HEALTH SYSTEM (AHS)is a leading public health care provider dedicated to caring, healing, teaching and serving all.
  • The program works by mobilizing teams across the continuum of care to implement American Heart Association/American College of Cardiology Foundation clinical treatment guidelines.

Athersys Hosting KOL Panel Event to Discuss TREASURE Data

Retrieved on: 
Mercoledì, Giugno 8, 2022
Biotechnology, Manufacturing, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Other Manufacturing, Science, Clinical Trials, Oxygen, Hospital, FAHA, Company, Stroke, Regenerative medicine, TPA, Houston Methodist Hospital, Nutrient, LinkedIn, Professor, Inflammation, Brain, Disability, Neuroscience, Patient, Private Securities Litigation Reform Act, Weill Cornell Medicine, Rehabilitation, KOL, Quality of life, Nerve, Social media, Twitter, Lists of people executed in the United States, Death, Pharmaceutical industry, Facebook, MD

The event will feature four key opinion leaders (KOLs) in the field of stroke and a statistician to share their perspectives on the topline data from the TREASURE study conducted by the Companys partner HEALIOS K.K.

Key Points: 
  • The event will feature four key opinion leaders (KOLs) in the field of stroke and a statistician to share their perspectives on the topline data from the TREASURE study conducted by the Companys partner HEALIOS K.K.
  • The TREASURE study is a randomized, double-blind placebo-controlled study evaluating MultiStem administration for the treatment of ischemic stroke.
  • Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.
  • Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization.

Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin

Retrieved on: 
Venerdì, Giugno 3, 2022
Niacin, Cholesterol, FAHA, Diabetes, ESPR, Doctor of Philosophy, Health information management, Ageing, Forward-looking statement, Security (finance), Awareness, Doctor of Pharmacy, U.S. Securities and Exchange Commission, Ezetimibe, PCSK9, FDA, Growth, GLOBE, Patient, LDL-C, ANN, Risk, Health, COVID-19, NASDAQ, Diagnosis, Twitter, Moyamoya disease, Fortis Healthcare, FACC, Education, Medical device, Pharmaceutical industry, Dietary supplement, MD, Esperies

ANN ARBOR, Mich., June 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced findings from a real-world analysis of more than 400,000 patients at high-risk for atherosclerotic cardiovascular disease (ASCVD). The findings were presented at the National Lipid Association Scientific Sessions in Scottsdale, Arizona.

Key Points: 
  • While LDL-cholesterol as a cardiovascular risk factor is well known, there remains a persistent gap in applying evidence-based therapies to reduce LDL-C.
  • These data reinforce the urgent need to improve the use of all appropriate statin and non-statin lipid-lowering therapies among at-risk patients.
  • The analysis examined deidentified electronic health records from approximately 90 US health systems between 2017 and 2018.
  • However, nearly one in ten (9.3%) of those recommended for primary prevention reported taking non-prescription Omega-3/fish oil supplements.

Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions

Retrieved on: 
Martedì, Maggio 31, 2022
Tendon rupture, Gout, Risk, Ezetimibe, Esperies, Moyamoya disease, Spasm, Pain, Pravastatin, Drug, FACC, Rupture, Disease, Abdominal pain, U.S. Securities and Exchange Commission, Atrial fibrillation, Lactation, Patient, Health, Kidney, COVID-19, FNLA, Mortality, FAHA, Uric acid, Shoulder, Pregnancy, Tablet, Fetus, Cholesterol, Forward-looking statement, Diet, Rotator cuff, Anemia, Achilles tendon, Back pain, Simvastatin, Security (finance), Bronchitis, Twitter, Growth, Bempedoic acid, Upper respiratory tract infection, Dietary supplement, Pharmaceutical industry, Hyperuricemia, Hyperuricemia, MD

ANN ARBOR, Mich., May 31, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced five abstracts have been accepted for presentation at the National Lipid Association Scientific Sessions (NLA 2022 Scientific Sessions) being held in-person in Scottsdale, Arizona.

Key Points: 
  • Limitations of Use: The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.
  • Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout.
  • Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
  • Esperion works hard to make our medicines easy to get, easy to take and easy to have.

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis

Retrieved on: 
Martedì, Maggio 17, 2022
Disease, Acute pericarditis, FACC, Food, Degenerative disease, Infection, Aspirin, FAHA, Pericarditis, Prednisone, Heart failure, Risk, Cancer, Prevalence, Fatigue, FESC, Hospital, News, Phase, Quality of life, Therapy, Clinical trial, COVID-19, TSX, Research, FRCP, Biomarker, CRP, Orphan, Cardiovascular disease, Inflammation, Death, Chest pain, Company, Tuberculosis, CVD, NRS, Cleveland Clinic, FDA, Cannabidiol, Recurrence, Fibrosis, Pericardium, Colchicine, Program, Chronic pain, Heart, C-reactive protein, History, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chair, Leadership, Patient, NASDAQ, Myocarditis, Epilepsy, IND, CRDL, Safety, Diagnosis, Pharmaceutical industry, Medical imaging, MD

Recurrent pericarditis is an orphan disease in the United States, thereby making CardiolRx eligible for orphan drug status under the FDA's Orphan Drug Designation program.

Key Points: 
  • Recurrent pericarditis is an orphan disease in the United States, thereby making CardiolRx eligible for orphan drug status under the FDA's Orphan Drug Designation program.
  • Cardiol's study is expected to enroll 25 patients at major clinical centers specializing in pericarditis in the United States.
  • The NRS is a validated clinical tool used across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis.
  • Cardiol believes there is a similar opportunity to develop its oral CardiolRx formulation as an orphan drug for the treatment of recurrent pericarditis.

Bringing the Human Connection Back to Healthcare

Retrieved on: 
Martedì, Maggio 10, 2022
FACC, Communication, Health care, Woman, Health equity, Cardiovascular disease, Human, Patient, The Human Connection, Partnership, Review, Equity, Health, Center, FAHA, CNN, Assistant, Solution, McCulloch, Multimedia, Medical device, Diversity, Forbes, Amazon, Northwell Health

NEW YORK, May 10, 2022 /PRNewswire/ -- Reigniting the Human Connection: A Pathway to Diversity, Inclusion, and Health Equity by Dr. Jennifer Mieres, Dr. Elizabeth McCulloch, and Dr. Michael Wright is available now. The book is published with ForbesBooks, the exclusive business book publishing imprint of Forbes, and is available on Amazon today.

Key Points: 
  • NEW YORK, May 10, 2022 /PRNewswire/ --Reigniting the Human Connection: A Pathway to Diversity, Inclusion, and Health Equity by Dr. Jennifer Mieres, Dr. ElizabethMcCulloch, and Dr. Michael Wright is available now.
  • The team at the Center for Equity of Care, Northwell's platform for Diversity, Inclusion and Health Equity has developed a foundational framework to improve healthcare outcomes.
  • Reigniting the Human Connection seeks to address the problem of healthcare delivery inequities by detailing systematic approaches to increasing diversity, inclusion, and health equity in the access and administration of contemporary healthcare.
  • Asked by the author's for his review of the book, CNN's Don Lemon calls Reigniting the Human Connection a "must-read for those in healthcare and beyond."

InspireMD Reports First Quarter 2022 Financial Results and Business Update

Retrieved on: 
Martedì, Maggio 10, 2022
COVID 19, Host, Biomedical sciences, KOL, Stent, Nasdaq, State university system, GLOBE, Holocene, Company, Stroke, Micronet, Food, Patient, TEL, Doctor of Philosophy, COVID, Clinical trial, Stenosis, FDA, Environment, Hospital, FACS, MD, Adoption, NSPR, IDE, Internet, FAHA, Conference, EPS, CEO, Growth, State University of New York, Pharmaceutical industry, Online gambling, Video game, Cleveland Clinic

First Quarter 2022 and Recent Highlights:

Key Points: 
  • First Quarter 2022 and Recent Highlights:
    CGuard revenues for the first quarter 2022 were $1,161,000, a 20% increase over the same period in 2021 on 1,910 stent systems sold.
  • Financial Results for the First Quarter ended March 31, 2022
    For the first quarter of 2022, revenue increased 17.6%, to $1,183,000, from $1,006,000 during the first quarter of 2021.
  • Gross profit for the first quarter of 2022 increased by $16,000, to $122,000, compared to a gross profit of $106,000 for the first quarter of 2021.
  • Management will host a conference call at 8:30AM ET today, May 10, 2022, to review financial results and provide an update on corporate developments.

Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology

Retrieved on: 
Lunedì, Maggio 2, 2022
The American Journal of Cardiology, COVID-19, Back pain, FACC, Atrial fibrillation, U.S. Securities and Exchange Commission, Forward-looking statement, Fetus, Diet, Efficacy, Rotator cuff, ESPR, Mortality, Simvastatin, Twitter, Pain, Shoulder, NASDAQ, Pregnancy, GLOBE, Upper respiratory tract infection, Safety, Moyamoya disease, Bempedoic acid, Security (finance), Abdominal pain, Disease, ANN, Ezetimibe, Rupture, Anemia, Kidney, Uric acid, Tablet, OLE, Health, Pravastatin, Cholesterol, FAHA, Lactation, Bronchitis, Achilles tendon, Growth, SE, Spasm, American Journal, Risk, Tendon rupture, Drug, Gout, Pharmaceutical industry, Dietary supplement, Esperies, Hyperuricemia, Cardiology, Hyperuricemia, Patient

ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL, in the American Journal of Cardiology.

Key Points: 
  • ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL, in the American Journal of Cardiology.
  • The paper, Long-term Safety and Efficacy of Bempedoic Acid in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (From the CLEAR Harmony Open-Label Extension Study), described the results from the 78-week, Phase 3, OLE study that followed the 52-week CLEAR Harmony Phase 3 study.
  • In the CLEAR Harmony study, patients were randomized 2:1 to bempedoic acid or placebo for 52 weeks.
  • Importantly, the safety profile of bempedoic acid in the OLE study was comparable to findings from the parent study and no new safety concerns were observed.